Otsuka has filed in Japan to expand Iclusig (ponatinib) into first-line treatment for adult Ph+ ALL, alongside a new 10 mg formulation to support dosing.
Written By: Karthik Teja Macharla, PharmD
Reviewed By: Pharmacally Editorial Team
Otsuka Pharmaceutical Co., Ltd. has submitted a supplemental application in Japan seeking approval to expand the indication of Iclusig (ponatinib hydrochloride) for the treatment of adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) in the first-line setting. The filing also includes a new 10 mg tablet formulation designed to support dosing in this setting.
Iclusig is an oral tyrosine kinase inhibitor originally discovered by Ariad Pharmaceuticals, Inc. and later acquired by Takeda Pharmaceutical Company Limited in 2017. Otsuka holds co-development and commercialization rights across nine Asian markets, including Japan.
The drug was approved in Japan in 2016 for patients with chronic myeloid leukemia (CML) who are resistant or intolerant to prior therapies, as well as for relapsed or refractory Ph+ ALL. The current submission aims to move Iclusig earlier in the treatment paradigm, addressing a significant unmet need in newly diagnosed patients.
Ph+ ALL is an aggressive leukemia subtype driven by the BCR::ABL1 tyrosine kinase resulting from the Philadelphia chromosome. It is characterized by rapid proliferation of malignant lymphoid precursor cells in the bone marrow and can lead to swift clinical deterioration if not effectively controlled.
Globally, Iclusig has continued to expand its clinical role. In the United States, the U.S. Food and Drug Administration granted accelerated approval in 2024 for Iclusig in combination with chemotherapy as an initial treatment for adult Ph+ ALL, building on its earlier use in resistant or T315I-mutated disease. The therapy has since been approved in multiple additional countries, including several markets across Asia.
Iclusig targets both native and mutated forms of BCR::ABL1, including the T315I mutation, which confers resistance to earlier-generation tyrosine kinase inhibitors. This broad activity supports its role in difficult-to-treat leukemias such as CML and Ph+ ALL.
If approved, the expanded indication in Japan would provide a new frontline treatment option for adults with Ph+ ALL, aligning with Otsuka’s strategy to address unmet medical needs through targeted therapies.
Reference
Otsuka Submits Application in Japan for Iclusig® for First-Line Treatment of Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia, 27 March 2026, Otsuka Submits Application in Japan for Iclusig® for First-Line Treatment of Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia｜March 27, 2026｜News Releases | Otsuka Pharmaceutical Co., Ltd.
About the Writer
Karthik Teja Macharla, PharmD is a Pharm.D. graduate with a strong interest in clinical research, pharmacovigilance, and medical writing. In his words, he is passionate about converting complex medical information into clear, evidence-based scientific communication, committed to contributing to patient safety and advancing healthcare through accurate and impactful medical content.